Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

NCT02071134 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.

Conditions Studied

Interventions

  • DEVICE Deep Brain Stimulation (DBS)

Study Locations (20)

Florida

  • University of Florida Shands Hospital — Gainesville
  • Mayo Clinic, Jacksonville — Jacksonville
  • University of Miami Hospital — Miami
  • Tallahassee Neurological Clinic, PA — Tallahassee
  • University of South Florida — Tampa

New York

  • Albany Medical College — Albany
  • Northwell Health Neuroscience Institute — Great Neck
  • University at Buffalo — Williamsville

California

  • Neurology and Pain Specialty — Aliso Viejo
  • Cedars Sinai Medical Center — Los Angeles

Colorado

  • University of Colorado — Aurora
  • St. Mary's Hospital and Medical Center — Grand Junction

Ohio

  • Cleveland Clinic Foundation — Cleveland
  • Ohio State University — Columbus

Idaho

  • St. Luke Regional Medical Center — Boise

Illinois

  • Rush University Medical Center — Chicago

Indiana

  • Methodist Hospital of Indianapolis — Indianapolis

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2014-03-04
Est. Completion 2038-12

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02071134

The ClinicalTrials.gov registry entry for NCT02071134 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention — of which Deep Brain Stimulation (DBS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02071134 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Florida, New York, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02071134 about?

NCT02071134 is a clinical study titled "Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry". The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming fea...

What is the current status of trial NCT02071134?

This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2014-03-04. Estimated completion is 2038-12.

What conditions does trial NCT02071134 study?

This clinical trial studies the following conditions: Parkinson's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02071134?

The interventions under investigation include: Deep Brain Stimulation (DBS) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02071134?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02071134 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial